期刊文献+

高效液相色谱法测定盐酸乙哌立松中的有机杂质

Determination of organic impurities in eperisone hydrochloride by HPLC
下载PDF
导出
摘要 目的建立高效液相色谱法测定盐酸乙哌立松中的有机杂质。方法采用CAPCELL pak C18MGⅡS5(4.6 mm×150 mm,5.0μm)色谱柱,柱温:30℃;流速:1.0 mL·min^-1;流动相:磷酸盐缓冲液(pH 7.5)-乙腈=40∶60;检测波长:254 nm,进样量:10μL。结果对于盐酸乙哌立松中的6个特定杂质,杂质A、B、C、D、E、F的线性范围分别为:0.030~2.26、0.013~2.25、0.017~2.25、0.048~2.15、0.017~2.14、0.027~2.26μg·m L^-1。杂质A、B、C、D、E、F的检测限分别为0.008、0.003、0.005、0.015、0.005、0.008μg·mL^-1。结论该方法可用于盐酸乙哌立松中有机杂质的检测。 Objective To establish an HPLC method for the determination of organic impurities in eperisone hydrochloride. Methods CAPCELL pak C18 MGⅡ S5(4.6 mm×150 mm, 5.0 μm) was used. The column temperature was 30 ℃, the flow rate was 1.0 mL·min^-1, the mobile phase was PBS(adjusted to pH 7.5)-acetonitrile(40∶60), the detection wavelength was 254 nm, and the sampling injection was 10 μL. Results The linear ranges for impurity A, B, C, D, E, and F was 0.030-2.26, 0.013-2.25, 0.017-2.25, 0.048-2.15, 0.017-2.14, and 0.027-2.26 μg·m L^-1. The detection limits of impurity A, B, C, D, E, and F was 0.008, 0.003, 0.005, 0.015, 0.005, and 0.008 μg·mL^-1. Conclusion The method is suitable for determining the organic impurities in eperisone hydrochloride.
作者 龙慧玲 刘钊 LONG Hui-ling;LIU Zhao(Hunan Center for Drug Evolution,Certification and ADR Monitoring,Changsha 410013;Harvest (Hunan) Pharmaceutical Co.,Ltd,Changsha 410200)
出处 《中南药学》 CAS 2019年第9期1529-1533,共5页 Central South Pharmacy
关键词 盐酸乙哌立松 有机杂质 高效液相色谱法 eperisone hydrochloride organic impurity HPLC
  • 相关文献

参考文献9

二级参考文献51

  • 1王明娟,李娅萍,胡昌勤.硅胶基质C_(18)柱的分类[J].药物分析杂志,2006,26(10):1521-1526. 被引量:4
  • 2[1]Tomio Takamatsu,Kasuhiko Yamazaki,Masanori Kayano.Determination of eperisone in human plasma by gas chromatography-mass spectrometry.J Chromato,1992,584∶261.
  • 3[2]Fumio Toba,Masayuki Ando,Tsukasa Hamada,et al.A sensitive determination of epridone in plasma by GC/MS.J Mass Spectrom Soc Jap,1993,41(4)∶335.
  • 4Mathew NT. Tension-tpye headache and miscellaneous primary headache disorders. In: Evans RW ,Mathew NT. (eds). Handbook of headache . 2nd USA: Lippincott Williams & Wilkins Inc, 2005,139 ~ 144
  • 5Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.Headache Classification Committee of the International Headache Society. Cephalalgia, 2004, 24(suppl1) : 1 ~152.
  • 6Ashina M, Bendtsen L, Jensen R, et al. Muscle hardness in patients with chronic tension-type headache: relation to actual headache state. Pain,1999, 79: 201~205.
  • 7Christensen M, Bendtsen L, Ashina M, et al. Experimental induction of muscle tenderness and headache in tension-type headache patients. Cephalalgia, 2005, 25: 1061 ~1067.
  • 8ZHANGWen-yu(张文裕) Eperisonehydrochloride(盐酸乙哌立松).World Pharmacy—synthetic drug[J].国外药学-合成药、生化药、制剂分册,1984,5(6):357-357.
  • 9Tomio Takamatsu,Kasuhiko Yaroazaki,Masanori Kayano.et al.Determination of eperisone in human plasma by gas chromatography-mass spectrometry.J Chromatogr.1992, 584:261
  • 10Van Gyseghem E, Jimidar M, Sneyers R, et al. Selection of reversed -phase liquid chromatographic columns with diverse selectivity to- wards the potential separation of impurities in drugs. J Chromatogr A,2004,1042(I -2) :69.

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部